Quick Answer
STRATA Skin Sciences, Inc. reported Total Revenue of $30.70 million for fiscal year 2025.
STRATA Skin Sciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $30.70M -8.5% |
$33.56M +0.6% |
$33.36M -7.8% |
$36.16M +20.6% |
$29.98M +29.8% |
$23.09M -26.9% |
| Revenue (ASC 606) | $30.70M -8.5% |
$33.56M +0.6% |
$33.36M -7.8% |
$36.16M +20.6% |
$29.98M +29.8% |
$23.09M -26.9% |
| Net Income | -$6.26M +37.9% |
-$10.09M +6.9% |
-$10.83M -95.2% |
-$5.55M -105.1% |
-$2.71M +38.7% |
-$4.41M -16.4% |
| Diluted EPS | -$1.35 +49.1% |
-$2.65 +14.5% |
-$3.10 -1837.5% |
-$0.16 | — | -$0.13 -18.2% |
| Total Assets | $33.03M -15.8% |
$39.23M -6.6% |
$42.02M -19.6% |
$52.27M +12.2% |
$46.59M -0.4% |
$46.78M -1.2% |
| Cash and Equivalents | $7.91M +9.0% |
$7.26M +7.0% |
$6.78M +24.8% |
$5.43M -56.8% |
$12.59M +18.7% |
$10.60M +30.4% |
| Long-Term Debt | $0.00 -100.0% |
$15.19M +1.0% |
$15.04M +101.2% |
$7.48M +2.1% |
$7.32M +597.0% |
$1.05M |
| Stockholders Equity | $2.98M -68.4% |
$9.43M -25.6% |
$12.69M -41.9% |
$21.83M -14.1% |
$25.41M -1.8% |
$25.89M -9.6% |
| R&D Expense | $421.0K -52.3% |
$883.0K -33.0% |
$1.32M +28.0% |
$1.03M -28.2% |
$1.43M +12.6% |
$1.27M +27.1% |
| Operating Income | -$4.70M +49.2% |
-$9.26M -7.6% |
-$8.60M -85.1% |
-$4.65M -5.6% |
-$4.40M -8.0% |
-$4.08M -35.4% |
| Gross Profit | $17.88M -7.0% |
$19.22M +4.1% |
$18.46M -15.2% |
$21.77M +9.7% |
$19.85M +40.4% |
$14.13M -30.3% |
| Shares Outstanding | 5.89M +41.2% |
4.17M +19.0% |
3.51M -89.9% |
34.72M +1.0% |
34.36M +1.7% |
33.80M +2.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $6.93M | -21.2% | -9.6% |
| Revenue (ASC 606) | September 30, 2025 | $6.93M | -21.2% | -9.6% |
| Net Income | September 30, 2025 | -$1.62M | +21.8% | +37.0% |
| Diluted EPS | September 30, 2025 | -$0.36 | +29.4% | +41.9% |
| Total Assets | September 30, 2025 | $30.72M | -22.0% | +4.2% |
| Cash and Equivalents | September 30, 2025 | $7.08M | +0.2% | +18.6% |
| Long-Term Debt | September 30, 2025 | $13.44M | -11.3% | -12.0% |
| Stockholders Equity | September 30, 2025 | $1.31M | -86.0% | +147.0% |
| R&D Expense | September 30, 2025 | $172.0K | -29.2% | +100.0% |
| Operating Income | September 30, 2025 | -$1.17M | +26.9% | +49.2% |
| Gross Profit | September 30, 2025 | $4.18M | -20.8% | -2.8% |
| Shares Outstanding | September 30, 2025 | 5.27M | +26.3% | +26.3% |
- STRATA Skin Sciences, Inc. reported Total Revenue of $30.70 million for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed a decrease of -8.5% in Total Revenue compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Revenue (ASC 606) of $30.70 million for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed a decrease of -8.5% in Revenue (ASC 606) compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Net Income of -$6.26 million for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed an increase of +37.9% in Net Income compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Diluted EPS of $1.35 per share (loss) for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed an increase of +49.1% in Diluted EPS compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Total Assets of $30.52 million for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed an increase of +3.5% in Total Assets compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Cash and Equivalents of $7.91 million for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed an increase of +9.0% in Cash and Equivalents compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Stockholders Equity of $2.91 million for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed an increase of +446.6% in Stockholders Equity compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported R&D Expense of $421.0 thousand for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed a decrease of -52.3% in R&D Expense compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Operating Income of -$4.70 million for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed an increase of +49.2% in Operating Income compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Gross Profit of $17.88 million for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed a decrease of -7.0% in Gross Profit compared to the prior fiscal year.
- STRATA Skin Sciences, Inc. reported Shares Outstanding of 5.89 million shares for fiscal year 2025.
- STRATA Skin Sciences, Inc. showed an increase of +41.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: